IBDEI17L ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21633,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,21633,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,21633,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,21634,0)
 ;;=204.02^^133^1317^2
 ;;^UTILITY(U,$J,358.3,21634,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21634,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,21634,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,21634,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,21635,0)
 ;;=204.12^^133^1317^48
 ;;^UTILITY(U,$J,358.3,21635,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21635,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,21635,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,21635,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,21636,0)
 ;;=204.21^^133^1317^113
 ;;^UTILITY(U,$J,358.3,21636,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21636,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,21636,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,21636,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,21637,0)
 ;;=204.20^^133^1317^114
 ;;^UTILITY(U,$J,358.3,21637,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21637,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,21637,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,21637,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,21638,0)
 ;;=204.22^^133^1317^112
 ;;^UTILITY(U,$J,358.3,21638,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21638,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,21638,1,5,0)
 ;;=5^Subacute LL in Relapse
 ;;^UTILITY(U,$J,358.3,21638,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,21639,0)
 ;;=203.02^^133^1317^102
 ;;^UTILITY(U,$J,358.3,21639,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21639,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,21639,1,5,0)
 ;;=5^Multiple Myeloma In Relapse
 ;;^UTILITY(U,$J,358.3,21639,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,21640,0)
 ;;=205.02^^133^1317^5
 ;;^UTILITY(U,$J,358.3,21640,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21640,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,21640,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,21640,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,21641,0)
 ;;=205.12^^133^1317^50
 ;;^UTILITY(U,$J,358.3,21641,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21641,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,21641,1,5,0)
 ;;=5^CML, In Relapse
 ;;^UTILITY(U,$J,358.3,21641,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,21642,0)
 ;;=V10.91^^133^1317^63
 ;;^UTILITY(U,$J,358.3,21642,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21642,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,21642,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,21642,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,21643,0)
 ;;=V10.91^^133^1317^73
 ;;^UTILITY(U,$J,358.3,21643,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21643,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,21643,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,21643,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,21644,0)
 ;;=465.9^^133^1318^72
 ;;^UTILITY(U,$J,358.3,21644,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21644,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,21644,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,21644,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,21645,0)
 ;;=462.^^133^1318^63
 ;;^UTILITY(U,$J,358.3,21645,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21645,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,21645,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,21645,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,21646,0)
 ;;=466.0^^133^1318^2
 ;;^UTILITY(U,$J,358.3,21646,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21646,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,21646,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,21646,2)
 ;;=^259084
